GLP-1 Medications and Eye Health: What We Know So Far

GLP-1 receptor agonists, including semaglutide and liraglutide, have become widely used in the management of type 2 diabetes and, increasingly, for weight loss. Their systemic benefits are well established, but their relationship with eye health remains an area of emerging study and active discussion.

There have been observations of worsening diabetic retinopathy in some patients after initiating therapy, likely related to rapid improvements in glycemic control rather than a direct toxic effect of the medication itself. This phenomenon is not new and has been described historically with intensive glucose lowering.

As use expands, particularly in patients without longstanding diabetes, there is growing interest in understanding whether there are direct ocular effects, how these medications may influence retinal vascular stability, and which patients may be at higher risk of visual complications. At this stage, the data is still evolving. There is no clear consensus suggesting that GLP-1 medications should be avoided due to eye-related concerns alone. However, it reinforces the importance of baseline eye examinations and appropriate follow-up, particularly in patients with pre-existing retinal disease.

This is an area I am actively engaged in, working with the Canadian Ophthalmological Society to help develop a position statement that reflects current evidence and provides clear guidance for both patients and providers. As more data becomes available, having a unified, evidence-based approach will be essential.

Organizations such as the Canadian Ophthalmological Society and the American Academy of Ophthalmology remain the gold standard sources for accurate, up-to-date information in eye health. Their role in reviewing evidence and providing balanced recommendations is particularly important in areas where clinical practice is evolving.